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Abstract 
BIRC8, also known as ILP-2, is a homologous 
protein of BIRC4, however, its function has seldom 
been addressed. Despite the similarity with other 
Inhibitory Apoptosis Proteins (IAPs), there is 
evidence that BIRC8 acts in a peculiar manner, by 
impeding apoptosis induced by BAX without 
directly inhibiting the activity of caspases. BIRC8 
expression has been detected in testis and 
lymphoblastic normal cells and, furthermore, it has 
been reported in different cancers, including breast 
carcinoma, hematological neoplasms, hepatocellular 
carcinoma, nasopharyngeal carcinoma, and 
neuroblastoma. However, the specific implications 
of such protein for treatment and prognosis must be 
further evaluated. In this review, current data on 
RNA, DNA, protein and the association of BIRC8 in 
cancer are presented. 
Keywords 
BIRC8; apoptosis; Inhibitory Apoptosis Proteins; 
cancer 
Identity 
Other names: Baculoviral IAP Repeat Containing 
8, Inhibitor of Apoptosis-Like Protein 2, IAP-Like 
Protein 2, Baculoviral IAP Repeat-Containing 
Protein 8, Testis-Specific Inhibitor of Apoptosis, 
ILP-2 
HGNC (Hugo): BIRC8 
Location: 19q13.42 
DNA/RNA 
Figure 1. BIRC8 structure.  BIRC8 (also kwon as ILP-2) 
protein structure presents 236 aa and is composed of a 
Baculovirus IAP Repeat (BIR) domain, an Ubiquitin-
associated (UBA) domain, and a RING finger domain. 
Description 
The entire BIRC8 gene is approximately 2 kb (start: 
53289601 and end: 53291622 bp; orientation: Minus 
strand). The BIRC8 cDNA contains 1 exon, 2022 
bases and generates a protein with 236 amino acids. 
Two additional transcripts are deposited in Ensembl 
(http://www.ensembl.org/): one processed transcript 
(1826 bases) and one transcribed processed 
pseudogene (1468), however, neither generated 
protein. 
Protein 
Description 
The BIRC8 protein contains a BIR3 domain, which 
is conserved among other Inhibitory Apoptosis 
Proteins (IAPs) members.  
Also, it contains an UBA domain, for ubiquitin 
binding, and a RING domain, with E3 ligase 
function. This protein presents a total of 236 amino 
acids and a molecular weight of 27 kDa.  
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The coding sequence of ILP-2 (BIRC8) is very 
similar to that of XIAP (ILP-1 or BIRC4), with 80% 
identity (95% homology) at the amino acid level 
(Richter et al., 2001).  
When analyzing the genomic organization of the 
BIRC4 locus, Lagacé et al. (2001) identified a cross-
reactive band that encodes a gene that expressed a 2 
kb novel transcript, homologous to BIRC4, called 
BIRC8.  
The same study demonstrated that overexpression of 
this gene protects cells against BAX-induced 
apoptosis.  
Additionally, it contains a putative open reading 
frame (ORF) that is homologous to the carboxy-
terminal end of BIRC4 (Lagacé et al., 2001). 
However, such similarity does not follow the 
biochemical interaction with caspases, supported by 
the fact that the putative caspase 9 interaction 
domain is a weak inhibitor and conformationally 
unstable, thus leading to an inability of BIRC8 to 
independently inhibit CASP9 (caspase 9) (Shih et 
al., 2005). 
Expression 
In normal tissues, BIRC8 (ILP-2) expression has 
only been detected in the cytoplasm of testis and 
lymphoblastoid cells (Richter et al., 2001; Lagacé et 
al., 2001). On the other hand, when assessed in 
cancer cells, BIRC8 was shown to be aberrantly 
expressed. 
Function 
BIRC8 is known to protect cells against intrinsic 
apoptosis induced by BAX and caspase 9, however, 
the function of this IAP has not been completely 
elucidated. Nevertheless, it has been shown that 
BIRC8 may not operate independently and requires 
cooperation with yet unidentified cellular proteins 
(Shin et al, 2005). Moreover, BIRC8 seems to play a 
role in immune-related functions due to its multiple 
leukocyte Ig-like receptors, natural killer cells, 
ICAMs and Fc receptors (FcRs) (Saleem et al., 
2013).  
Furthermore, BIRC8 undertakes a role in 
transformation and progression of different cancers, 
by protecting cells from BAX-mediated apoptosis 
(Chuturgoon et al., 2015; Glodkowska-Mrowka et 
al., 2013; Zhu et al., 2018). 
Homology 
At the amino acid sequence level, BIRC8 presents 
80% identity and 95% homology with BIRC4. There 
are only a few data deposited on BIRC8 homology 
among different species. Still, it has been shown that 
there is 98.3% and 98.6% identity in BIRC8 protein 
and DNA, respectively, between Homo sapiens and 
Pan troglodytes 
(http://www.ncbi.nlm.nih.gov/homologene). 
Mutations 
Somatic 
Among the 148 mutations reported in COSMIC 
(Catalogue of Somatic Mutations in Cancer; 
http://cancer.sanger.ac.uk/cancergenome/projects/c
osmic) for BIRC8, 77.03% are missense 
substitutions, 17.57% synonymous substitutions, 
and 8.11% nonsense substitutions. Similar findings 
are reported in cBioPortal 
(http://www.cbioportal.org): among the 52666 
cancer samples accessed, somatic mutations in 
BIRC8 occur in 0.3% of the tested samples 
(corresponding to 145 mutations, of which 127 are 
missense substitutions, 17 truncated genes, and 1 
other mutation). 
Implicated in 
Breast cancer 
BIRC8 expression was evaluated in serum samples 
from patients with breast cancer and compared to 
that of either healthy women, women bearing 
galactophore hyperplasia, patients, with other types 
of cancer, or to post-breast cancer surgery patients. 
Increased expression was observed in patients with 
breast cancer when compared to those bearing other 
cancers or other breast pathologies, indicating that 
serum levels of BIRC8 may be a biomarker for breast 
cancer (Xiang et al., 2012).  
BIRC8 overexpression was also observed in 59 
tissue paraffin-embedded blocks, which including 35 
breast cancer tissues and 24 galactophore 
hyperplasia tissues and in the breast cancer cell lines 
HCC-1937, MX-1 and MCF-7. Still, to verify the 
precise role of BIRC8, silencing experiments 
revealed that inhibition of BIRC8 induced apoptosis, 
corroborating to its pro-survival function in breast 
cancer cells.  
Additionally, BIRC8 depletion led to reduced breast 
cell migration, demonstrating that this gene is not 
only involved in sustaining breast cancer, but also in 
supporting the cell's migratory capacity (Zhu et al., 
2018). 
Chronic myeloid leukemia 
BIRC8 expression was evaluated in chronic myeloid 
leukemia (CML) patients and, opposite to what is 
expected for BIRC genes in tumor progression, a 
significant decrease in BIRC8 expression was 
observed following the development of tyrosine 
kinase inhibitor resistance in chronic phase CML 
patients. Such observation allows for speculation 
that BIRC8 does not display a classical apoptosis 
inhibition function in leukemia cells (Glodkowska-
Mrowka et al., 2013). 
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Hepatocellular carcinoma 
Liver cancer induced by the mycotoxin fumonisin 
B1 (FB1), produced by Fusarium sp., leads to 
apoptosis resistance in the HepG2 cell line.  
A panel of 84 apoptosis-associated genes was 
evaluated after HepG2 cell exposure to FB1 and 
increased BIRC8 mRNA (5.7 fold) and protein (2.3 
fold) expressions were detected, implying that 
BIRC8 contributes to liver tumorigenesis 
(Chuturgoon et al., 2015). 
Myelodysplastic syndrome 
BIRC8 levels, along with Apallon and BIRC7, were 
significantly increased in bone marrow cells of 
myelodysplastic syndromes, even when compared to 
leukemia cells.  
Such feature may suggest that these BIRC proteins 
are transiently overexpressed at the very early stage 
of leukemia transformation, acting as a trigger for the 
expression of other IAPs members, like BIRC5 and 
BIRC4 (Abe et al., 2005). 
Nasopharyngeal Carcinoma 
BIRC8 expression mediated by an up-regulation of 
the Rho-guanine nucleotide exchange factor 3 gene, 
ARHGEF3, contributed to the onset and progression 
of nasopharyngeal carcinoma.  
The factor ARHGEF3 plays a key role in the growth 
of such cancer.  
It has been demonstrated that depletion of 
ARHGEF3, using siRNA, induced apoptosis by a 5-
fold down-regulation of BIRC8 expression in 
nasopharyngeal carcinoma cell lines (Liu et al., 
2016). 
Neuroblastoma 
BIRC8 was inhibited in neuroblastoma xenograft 
models after treatment with Azadirachta indica 
extract, contributing to radiosensitization and 
leading to cell death.  
This action was caused through the activation of pro-
apoptotic signaling and inhibition of antiapoptotic 
genes, including the IAP members NAIP, BIRC6, 
and BIRC8 (Veeraraghavan et al., 2011). 
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